James Thrasher

Researcher

UAMS

Also affiliated: Howard University (1981); Southern Illinois University School of Medicine (1978–1981); University of Arkansas Medical Center (1996–2025); Ark Medical Center (2017); Arkana Laboratories (2024); Medtronic (United States) (2023); Arkansas Cardiology (2021–2025); Manitoba Beekeepers' Association (2019); Iowa Diabetes and Endocrinology Research Center (2021); Arkansas Department of Agriculture (2012–2015); Intuitive Surgical (United States) (2015–2019); South University (2012)

Faculty Researcher

20 h-index 36 pubs 5,520 cited

Research Areas

Biomedical Subjects

OverviewAI-generated summary

James Thrasher's research focuses on the evaluation and improvement of diabetes management technologies, particularly closed-loop insulin delivery systems. His work investigates the safety and glycemic outcomes associated with these advanced systems in diverse patient populations, including adolescents and adults with Type 1 diabetes, as well as adults with insulin-requiring Type 2 diabetes.

His publications detail the performance of systems such as the MiniMed™ Advanced Hybrid Closed-Loop System and the MiniMed™ 780G system, examining factors like infusion set survival rates and the effectiveness of recommended settings in real-world use. Thrasher also contributes to studies on novel therapeutic agents, including investigations into once-weekly insulin formulations for Type 2 diabetes management.

With an h-index of 20 and over 5,000 citations across 36 publications, Thrasher's scholarship reflects a sustained contribution to the field of diabetes technology and pharmacotherapy. His recent activity indicates ongoing engagement in clinical trials and research evaluating the next generation of diabetes care devices and treatments.

Metrics

h-index: 20
Publications: 36
Citations: 5,520

Selected Publications

Safety and Glycemic Outcomes of the MiniMed 780G System with a Disposable All-in-One Sensor (2025)

Diabetes Technology & Therapeutics 3 citations DOI OpenAlex
Evaluation of Extended Infusion Set Performance in Adults with Type 1 Diabetes: Infusion Set Survival Rate and Glycemic Outcomes from a Pivotal Trial (2022)

Diabetes Technology & Therapeutics 25 citations DOI OpenAlex
Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial (2019)

Diabetes Technology & Therapeutics 8 citations DOI OpenAlex
Insulin Lispro with Continuous Subcutaneous Insulin Infusion is Safe and Effective in Patients With Type 2 Diabetes: A Randomized Crossover Trial of Insulin Lispro Versus Insulin Aspart (2014)

Endocrine Practice 5 citations DOI OpenAlex
Efficacy and Safety of Linagliptin in Black/African American Patients with Type 2 Diabetes: A 6-Month, Randomized, Double-Blind, Placebo-Controlled Study (2013)

Endocrine Practice 20 citations DOI OpenAlex